Prognostic and predictive value of circulating tumour DNA (ctDNA) by amplicon-based next generation sequencing (NGS) of advanced pancreatic cancer (APC) in a phase I trial of oxaliplatin capecitabine and irinotecan (OXIRI) triplet chemotherapy.

Amanda Oon Lim Seet,Su Pin Choo,David Wai-Meng Tai,Justina Yick Ching Lam,Tira Jing Ying Tan,Daniel Shao-Weng Tan,Aaron C. Tan,Yvonne Chang,Balram Chowbay,Matthew C.H. Ng

Prognostic and predictive value of circulating tumour DNA (ctDNA) by amplicon-based next generation sequencing (NGS) of advanced pancreatic cancer (APC) in a phase I trial of oxaliplatin capecitabine and irinotecan (OXIRI) triplet chemotherapy.

2020

Amanda Oon Lim Seet
Su Pin Choo
David Wai-Meng Tai
Justina Yick Ching Lam
Tira Jing Ying Tan
Daniel Shao-Weng Tan
Aaron C. Tan
Yvonne Chang
Balram Chowbay
Matthew C.H. Ng

730Background: Tumoral KRAS mutations (KRASmt) are detected in ~80% of APC and associated with a negative prognosis. Digital droplet PCR (ddPCR) has high sensitivity for circulating KRASmtbut narro...

Keywords:

Irinotecan
Pancreatic cancer
Cancer research
Amplicon
Oxaliplatin
DNA sequencing
DNA
Medicine
Chemotherapy
Pathology
Capecitabine
KRAS

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations